If you have a investment time horizon of more than a week or month, the call was IMO pretty solid.
-2 Additional Phase 3 Trials in RCC & HCC for Cometrique w/FDA and EU approved trial designs
- Ended 2012 with $637 Million in Cash
- Expect to end 2013 with over $400 Million in Cash
- Comet trials still on track to read out in 2014
Anyone concerned about the revenue miss is simply in the wrong sector. I'm pretty happy with what I heard yesterday and looking to add a little in this price range.
"Anyone concerned about the revenue miss is simply in the wrong sector"
This is not a profitable Company, not yet.
So who cares for that -0.06?
When it starys the big sales era, then we'll look closer to the EPS.
At this point, EXEL is still in the "bonds & projections" mode.
Today is only speculation.
Let them play.
We'll see who laugh when trial data are out..... and BPs' interest grows.